HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical firm working to create best-in-class most cancers therapies, at present introduced that the Compensation Committee of the Firm’s Board of Administrators granted ten new staff choices to buy a complete of 190,200 shares of the Firm’s widespread inventory at an train value per share of $25.28, which was the closing value on July 8, 2020. The inventory choices had been granted pursuant to the Firm’s 2020 Inducement Plan, which was permitted by the Firm’s Board of Administrators in January 2020 pursuant to the “inducement exception” below NYSE Listed Firm Guide Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is an oncology-focused biopharmaceutical firm leveraging its deep cross-disciplinary experience to find extremely differentiated therapies and to develop a broad portfolio of novel combos addressing important unmet wants. AB928, the primary and solely twin A2a/A2b adenosine receptor antagonist within the clinic, is being evaluated in a number of Section 1b/2 research throughout a number of indications, together with prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast and renal cell cancers. AB680, the primary small-molecule CD73 inhibitor within the clinic, is in Section 1 improvement for first-line therapy of metastatic pancreatic most cancers. AB154, an anti-TIGIT monoclonal antibody, is in Section 2 improvement for first-line therapy of metastatic non-small cell lung most cancers together with zimberelimab and AB928. Zimberelimab (AB122), Arcus’s anti-PD1 monoclonal antibody, is being evaluated in a Section 1b examine as monotherapy for cancers with no permitted anti-PD1 therapy choices, in addition to in combos throughout the portfolio. For extra details about Arcus Biosciences, please go to www.arcusbio.com.
Supply: Arcus Biosciences